BioRestorative Therapies, Inc. (FRA:9OF)

Market Cap	8.52M -29.6%
Revenue (ttm)	326.77K +1.7%
Net Income	-10.80M
EPS	-1.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	194
Open	0.9200
Previous Close	0.9250
Day's Range	0.9200 - 0.9200
52-Week Range	0.8450 - 2.2200
Beta	n/a
RSI	45.08
Earnings Date	Mar 27, 2026

About BioRestorative Therapies

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Lance Alstodt
• Employees: 11
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9OF

Financial Performance

In 2024, BioRestorative Therapies's revenue was $401,000, an increase of 175.03% compared to the previous year's $145,800. Losses were -$8.98 million, -13.81% less than in 2023.

Financial numbers in USD